Tables
- Table 1—
Primer sequences for iPLEX™ genotyping assay for the nicotinic acetylcholine receptor α5 and α3 subunit single nucleotide polymorphism (SNP)
SNP ID First PCR primer Second PCR primer Extension primer rs16969968 ACGTTGGATGCACGG ACGTTGGATGTCTAGAAA CATTGGAAGCTGCGCTC ACATCATTTTCCTTC CACATTGGAAGC rs1051730 ACGTTGGATGCAGCA ACGTTGGATGTCAAGGAC TCATCAAAGCCCCAGGCTA GTTGTACTTGATGTC TATTGGGAGAGC iPLEX™ is manufactured by Sequenom, San Diego, CA, USA.
- Table 2—
Study characteristics
Parameter Lung cancer COPD Control smokers Subjects n 454 458 488 Males 53 59 60 Age yrs 69±10 66±9 65±10 Smoking history Current smoker 35 40 48 Age started smoking yrs 18±4 17±3 17±3 Length of time smoked yrs 41±12 42±11 35±11 Pack-yrs 41±25* 47±20* 40±19* Cigarettes·day−1 20±10 23±9 24±11 Time since quitting yrs 11.4±6.7 9.8±7.4 13.9±8.1 History of other exposures Work dust 63* 59* 47* Work fume 41 40 38 Asbestos 23* 22* 16* Family history COPD 33 37 28 Lung cancer 19* 11* 9* Lung function FEV1 L 1.86±0.48* 1.25±0.48* 2.86±0.68* FEV1 % pred 73* 46* 99* FEV1/FVC 64±13* 46±8* 78±7* Spirometric COPD# 57* 100* 0* Data are presented as % or mean±sd, unless otherwise stated. COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in one second; % pred: % predicted; FVC: forced vital capacity. #: according to Global Initiative for Chronic Obstructive Lung Disease stage 2. *: p<0.05.
- Table 3—
Genotype frequencies for the nicotinic acetylcholine receptorα5 subunit single nucleotide polymorphism (rs16969968) in chronic obstructive pulmonary disease (COPD) and lung cancer (LC) cohorts compared with smoking controls
Subjects n Call rate GG GA AA OR (95% CI)# p-value# Primary cohorts Controls 475 97 225 (47) 205 (43) 45 (9) COPD 445 97 166 (37) 219 (49) 60 (14) 1.5 (1.0–2.3)# 0.06 LC 437 96 170 (39) 199 (46) 68 (16) 1.8 (1.2–2.7) 0.005 Subgroup analyses COPD and LC+COPD 706 252 (36) 344 (49) 110 (16) 1.8 (1.2–2.6) 0.002 LC+COPD¶ 261 86 (33) 125 (48) 50 (19) 2.3 (1.4–3.6) 0.0002 LC only 168 81 (48) 69 (41) 18 (11) 1.2 (0.6–2.1.) 0.64 Data are presented as % or n (%), unless otherwise stated. OR: odds ratio; 95% CI: 95% confidence interval. #: AA versus GA/GG compared with matched smoking controls (Mantel–Haenszel); ¶: AA versus GA/GG compared with COPD and lung cancer alone (OR 2.0, 95% CI 1.1–3.7; p = 0.02).
- Table 4—
Genotype frequencies for the nicotinic acetylcholine receptorα5 subunit single nucleotide polymorphism (rs16969968) across all cohorts stratified by chronic obstructive pulmonary disease (COPD) and lung cancer (LC)
Subjects n GG GA AA OR (95% CI)# p-value# Cohorts stratified by COPD No COPD 643 306 (48) 274 (43) 63 (10) COPD 706 252 (36) 344 (49) 110 (16) 1.7 (1.2–2.4) 0.002 Cohorts stratified by LC No LC¶ 920 391 (43) 424 (46) 105 (11) LC+ 437 170 (39) 199 (46) 68 (16) 1.4 (1.0–2.0) 0.03 Data are presented as n (%), unless otherwise stated. OR: odds ratio; 95% CI: 95% confidence interval. #: AA versus GA/GG (Mantel–Haenszel); ¶: 48% with no LC have COPD; +: 60% with LC have COPD.